Business
Result of Annual General Meeting
Result of Annual General Meeting.
About this update from Avacta Group Plc
[{"type":"text","content":"\n\n \n \n28 June 2023\n \nAvacta Group plc\n \n(\"Avacta\" or the \"Company\" and, together with its subsidiary undertakings, the \"Group\")\n \nResult of Annual General Meeting\n \nAvacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to announce that all resolutions have been duly passed by shareholders at the Annual General Meeting held today. \n \nThe full text of each resolution is set out in the Notice of Annual General Meeting, included in the 2022 Annual Report, which is available under the Investor Resources section of the Company's website https://avacta.com/investors/investor-resources/.\n \nAll presentation materials provided to shareholders, including slide decks and posters, can also be found here.\n \n-Ends-\n \nFor further information from Avacta Group plc, please contact:\n \n\n\n\nAvacta Group plc\nAlastair Smith, Chief Executive Officer\nTony Gardiner, Chief Financial Officer\nMichael Vinegrad, Group Communications Director\n \n\n\nTel: +44 (0) 1904 21 7070\nwww.avacta.com\n\n\n\n\nStifel Nicolaus Europe Limited (Nomad and Broker)\nNicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Dhiren Suares / William Palmer-Brown\n \n\n\nTel: +44 (0) 207 710 7600\nwww.stifel.com\n\n\n\n\nFTI Consulting (Financial Media and IR)\nSimon Conway / Alex Shaw\n \n\n\nTel: +44(0) 203 727 1000\[email protected]\n\n\n\n\nZyme Communications (Trade and Regional Media)\nLily Jeffery\n \n\n\nTel: +44 (0)7891 477 378\[email protected]\n\n\n\n \nAbout Avacta Group plc - www.avacta.com\n \nAvacta Group plc is a life sciences company working to improve people's health and well-being through innovative oncology drugs and powerful diagnostics. Operating through two divisions, Diagnostics and Therapeutics, the Group's mission is to provide professionals and consumers with solutions that improve healthcare, fitness and well-being.\n \nAvacta's Therapeutics Division, a clinical stage oncology drug innovator, is building a wholly owned pipeline of novel Affimer® immunotherapies and pre|CISION™ tumour targeted chemotherapies. This approach is designed to address the lack of a durable response to current cancer immunotherapies...